Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report

ALK rearrangements are identified as driver mutations in non-small-cell lung cancer (NSCLC). EML4 is the most common partner of ALK rearrangements. Here, we reported a patient with lung adenocarcinoma who was identified with EML4-ALK mutations when he progressed on an immune checkpoint inhibitor. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zhifeng, Guo, Junhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062446/
https://www.ncbi.nlm.nih.gov/pubmed/37007089
http://dx.doi.org/10.3389/fonc.2023.1082115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062446/
https://www.ncbi.nlm.nih.gov/pubmed/37007089
http://dx.doi.org/10.3389/fonc.2023.1082115

Ejemplares similares